In this issue:

› Dendrimer-Docetaxel to enter human clinical trials

› VivaGel® Phase 3 trial for prevention of recurrent BV

› VivaGel®-coated condom: Consumer feedback

› Impressive results for Dendrimer-Enhanced Oxaliplatin

› Progress continues in agrochemical activities

› Appointment of Rob Thomas

› SPL TV – a new channel

Download: Shareholder Update: December 2013 ( pdf file, 1MB)

Starpharma today announced that Mr Robert Thomas has been appointed to the Board as a non-executive director with effect from 4 December 2013.

Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 22^nd November 2013. Results of voting were released following the meeting. Resolution 5 was withdrawn prior to the meeting.

Australian Financial Review Journalist, Bina Brown reported on an Australian equities market shift away from resources into biotech and included Starpharma as a company to watch. The article noted the recent positive data showing that the Company’s delivery technology can make commonly use cancer drugs work a lot better as well as reduce side effects that can result in patients having to stop treatment.

 “[Starpharma’s] delivery technology can not only make commonly used cancer drugs work a lot better, but can get rid of the main side-effects that can mean cancer patients have to stop using them.. ‘If the human data is anything like what we have seen in preclinical ­studies, this will be a total game changer.’”

Starpharma today announced the selection of Mr Robert Thomas for appointment to the Board as a non-executive director.  He will be appointed in December 2013 and will assume the role of Chairman mid-year when Mr Peter Bartels retires as part of a deliberate succession plan and board renewal.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2013.

The cash balance at 30 September 2013 was $31.5 million, a net cash burn of $2.3 million for the quarter.

Starpharma today announced additional positive results for its dendrimer formulation of the major chemotherapeutic, docetaxel (Taxotere^®), ahead of its advancement into clinical trials later this year.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16^th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.

 Watch the video (external link)

Starpharma CEO Dr Jackie Fairley joined Sky News to discuss the positive results of the Company’s pre-clinical trial of Dendrimer-Enhanced Oxaliplatin. Starpharma’s dendrimer version of the blockbuster colon and colorectal cancer drug was shown to be less neurotoxic than conventional oxaliplatin.

View the Interview

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced further positive results for its Dendrimer-Enhanced Oxaliplatin (DEO), specifically that its dendrimer version of oxaliplatin results in a significant reduction in the serious neurotoxicity commonly seen with oxaliplatin.